Navigation Links
Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
Date:9/6/2007

mal responses was, as previously reported, 44% (18 out of 41 patients evaluable for response). Of the 18 responding patients (44%), 8 out of 14 patients were bortezomib-nave (57%); 7 out of 16 patients were bortezomib-pretreated patients (44%); and 3 out of 11 patients were bortezomib-refractory (27%). Responses in the bortezomib-refractory patients continue to show prolonged duration (at least 10 months at the time of data presentation at ASCO in June 2007) and meaningful reduction of serum/urinary M-protein (greater than 89%). The combination of tanespimycin and bortezomib was well-tolerated.

Kosan has been granted orphan drug designation for tanespimycin in multiple myeloma in both the US and European Union.

About Kosan

Kosan Biosciences is a biotechnology company advancing two new classes of anticancer agents through clinical development -- Hsp90 (heat shock protein 90) inhibitors and epothilones. Kosan is leveraging its proprietary discovery platform to generate a pipeline of potentially significant product candidates, primarily in the area of oncology.

Hsp90 inhibitors have a novel mechanism of action targeting multiple pathways involved in cancer cell growth and survival. Tanespimycin (KOS-953) is being tested in combination with bortezomib in patients with multiple myeloma in a registration program called TIME. Tanespimycin is also being studied in HER2-positive metastatic breast cancer in combination with Herceptin, and as monotherapy in metastatic melanoma. Intravenous and oral formulations of Kosan's second-generation Hsp90 inhibitor, alvespimycin (KOS-1022), are being evaluated in Phase 1 clinical trials in hematological cancers and in HER2-positive metastatic breast cancer.

Epothilones inhibit cell division with a mechanism of action similar to taxanes, one of the most successful classes of anti-tumor agents. KOS-1584 is in Phase 1 clinical trials in patients with solid tumors. Kosan's epothilone program is partnered with R
'/>"/>

SOURCE Kosan Biosciences Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
2. Kosan Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Epothilone KOS-1584 at ASCO
3. Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising Antitumor Activity in Multiple Myeloma at ASCO
4. Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO
5. Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR
6. Kosan Presents Preclinical Antitumor and Safety Data On Next-Generation Epothilone KOS-1803 at AACR
7. Kosan Presents Data on Cardiac Safety Profile of Hsp90 Inhibitor Tanespimycin (KOS-953) at AACR
8. Kosan Announces Data Presentations at Upcoming AACR Annual Meeting
9. Sirion Therapeutics Receives Orphan Drug Designation for Ophthalmic Drug to Treat Viral Eye Infection
10. Protalix BioTherapeutics, Inc. Receives Approval from the FDA to Initiate a Phase III Clinical Trial of prGCD
11. DUSA Pharmaceuticals Receives Orphan Drug Desi gnation for Levulan PDT to Treat Esophage al Dysplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Valeant Pharmaceuticals International, Inc. (NYSE: ... company,s Bridgewater, New Jersey location ... Drug Administration (FDA) relating to an inspection in June ... Aesthetic injectable, which was divested to Galderma S.A. in ... Valeant,s contract manufacturers (rather than Valeant,s own internal manufacturing) ...
(Date:9/30/2014)... 30, 2014  Based on its recent analysis ... Sullivan recognizes Ventana Medical Systems, Inc. (Ventana), a ... North American Frost & Sullivan Award for Technology ... with a focus on innovation and improving patient ... tissue-based cancer diagnostic solutions for patients worldwide. ...
(Date:9/30/2014)... The report based on "Nutraceutical ... Growth and Forecast, 2007 - 2017," elaborated by Transparency ... billion in 2012 and is further expected to reach ... of 7.3% from 2012 to 2017. Nutraceutical ... especially to prevent chronic diseases that may occur to ...
Breaking Medicine Technology:Valeant Pharmaceuticals' Bridgewater Location Receives Warning Letter From FDA 2Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market 2Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market 3Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market 4Nutraceutical Ingredient Market Will Reach USD 33.6 Billion Globally in 2018: Transparency Market Research 2Nutraceutical Ingredient Market Will Reach USD 33.6 Billion Globally in 2018: Transparency Market Research 3Nutraceutical Ingredient Market Will Reach USD 33.6 Billion Globally in 2018: Transparency Market Research 4
... , REDWOOD CITY, Calif., Dec. 15 ... results from five new studies on its Onco type ... currently use to predict the likelihood of chemotherapy benefit and ... were presented at the 32nd Annual CTRC-AACR San Antonio Breast ...
... , , , WALTHAM, Mass., Dec. 15 Decision Resources, ... pharmaceutical and healthcare issues, finds that an overall survival benefit ... European oncologists in their decision to prescribe a novel agent ... The new Special European Physician & Payer Forum report entitled ...
Cached Medicine Technology:Genomic Health Announces New Data Reinforcing Clinical Utility of Oncotype DX(R) in Multiple Breast Cancer Populations 2Genomic Health Announces New Data Reinforcing Clinical Utility of Oncotype DX(R) in Multiple Breast Cancer Populations 3Genomic Health Announces New Data Reinforcing Clinical Utility of Oncotype DX(R) in Multiple Breast Cancer Populations 4Genomic Health Announces New Data Reinforcing Clinical Utility of Oncotype DX(R) in Multiple Breast Cancer Populations 5Genomic Health Announces New Data Reinforcing Clinical Utility of Oncotype DX(R) in Multiple Breast Cancer Populations 6Genomic Health Announces New Data Reinforcing Clinical Utility of Oncotype DX(R) in Multiple Breast Cancer Populations 7For Breast Cancer Treatment, an Agent That Can Achieve an Overall Survival Benefit Would Pose the Greatest Challenge to Avastin's Dominance in Europe 2For Breast Cancer Treatment, an Agent That Can Achieve an Overall Survival Benefit Would Pose the Greatest Challenge to Avastin's Dominance in Europe 3
(Date:9/30/2014)... 30, 2014Levothyroxine (L-T4), long the standard of care ... but some individuals do not regain optimal health ... may help to explain these differences. An expert ... thyroid hormone replacement reviewed the latest studies on ... whether a change to the current standard of ...
(Date:9/30/2014)... at the University of Pittsburgh School of Dental Medicine ... the National Institute of Dental and Craniofacial Research, part ... exploration of the genetic roots of cleft lip and ... populations in Colombia, Nigeria, the Philippines and Pennsylvania. ... the lip or palate that can form when a ...
(Date:9/30/2014)... muscles contain few stem cells, heart tissue is ... Now Tel Aviv University researchers are literally setting ... , Dr. Tal Dvir and his graduate student ... of Materials Science and Engineering, and Center for ... and nanotechnological tools ranging in size from ...
(Date:9/30/2014)... a very valuable procedure by which to screen ... seems that healthy Americans who do undergo this ... before they actually should. Gina Kruse of ... advise that endoscopists stick to the national guidelines ... Journal of General Internal Medicine , published by ...
(Date:9/30/2014)... SIMpalm, the top iPhone app development ... great social networking music sharing experience. Lyricz LLC officially ... and iPod touch®. The App allows users to take ... pre-populated ITunes account. This app also gives users the ... photo of their choice to the snippet of selected ...
Breaking Medicine News(10 mins):Health News:New hypothyroidism treatment guidelines from American Thyroid Association 2Health News:Pitt team searches for genetic roots of cleft lip, palate 2Health News:A heartbeat away? Hybrid 'patch' could replace transplants 2Health News:Americans undergo colonoscopies too often, study finds 2Health News:LYRICZ App for iPhone®, Helps You Share Images with Music to Inspire and Influence 2
... need in ... exploding HSA market, ... an online education, enrollment, and incentive support platform for,Group Health ... Health platform (http://www.fontishealth.com ) simplifies the,administration and use of ...
... The following is a,statement regarding Microsoft,s announcement of ... It is encouraging that companies like Microsoft, Google ... (PHR) products and systems,that people can use to manage ... follow suit. Having ready access to your own,health information ...
... tick-borne illness has nearly tripled, research shows , THURSDAY, Oct. ... fever in the United States almost tripled from 695 in ... fatal disease is caused by Rickettsia rickettsii bacteria, ... dog tick or Rocky Mountain wood tick. Within 14 days ...
... 4, 2007 MedImmune, Inc. today announced results from ... Society of America (IDSA) 45th Annual Meeting adding to ... RSV is a viral pathogen that produces annual ... manifests cold-like symptoms in healthy children, it can prove ...
... General,Dentistry (AGD) was extremely disappointed by President Bush,s ... Program (SCHIP),reauthorization bill. The SCHIP bill agreed upon ... important and beneficial dental,provisions intended to provide for ... Bush, who had threatened to veto this bill,followed ...
... Health Coaching Service,with HealthVault,s Best-Of-Breed Health ... and Compatibility with Other Related Devices,and ... LiveHealthier,announced today the compatibility of its ... HealthVault, the newly launched consumer health,platform. ...
Cached Medicine News:Health News:Fontis Health Launches Online HSA Support System 2Health News:Statement Regarding Microsoft's Announcement of New Services to Help People Store Their Health Information Online 2Health News:Surge in U.S. Cases of Rocky Mountain Spotted Fever 2Health News:Medimmune announces phase 2 safety data for anti-RSV antibody and national RSV surveillance results 2Health News:AGD Concerned With Presidential Veto of SCHIP Reauthorization Bill 2Health News:AGD Concerned With Presidential Veto of SCHIP Reauthorization Bill 3Health News:LiveHealthier Announces Its Health and Wellness Coaching Solution for Employer Groups is Now Compatible With Microsoft HealthVault 2
Used for the retrieval of stones, stents, or other objects in the urinary tract under direct vision. Retrieval Forceps are designed for use through rigid or flexible endoscopes. Supplied sterile in p...
... technology allows the grasper ... a shorter length and ... the stone. The Unidex ... one-handed operation. Supplied sterile ...
Bugbee Fulgurating...
Fulgurating Electrode, 2 F...
Medicine Products: